Tafinlar (dabrafenib) / Novartis, BeiGene  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tafinlar (dabrafenib) / Novartis, BeiGene
COMBI-AD, NCT01682083 / 2012-001266-15: Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma ().

Checkmark Data from COMBI-AD trial in combination with Mekinist for melanoma at ASCO 2020
May 2020 - May 2020: Data from COMBI-AD trial in combination with Mekinist for melanoma at ASCO 2020
Checkmark Data from COMBI-AD trial in combination with Tafinlar for melanoma at ASCO 2020
May 2020 - May 2020: Data from COMBI-AD trial in combination with Tafinlar for melanoma at ASCO 2020
Checkmark From COMBI-AD trial in combination with Mekinist at ASCO 2020
More
Completed
3
870
Europe, Canada, Japan, US, RoW
Dabrafenib, GSK2118436, Trametinib, GSK1120212, Placebos
Novartis Pharmaceuticals
Melanoma
06/17
07/23
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
COMBI-i, NCT02967692 / 2016-002794-35: A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Checkmark From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Checkmark From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Checkmark From COMBI-i trial in combination with spartalizumab and Mekinist for BRAFV600 metastatic melanoma
More
Active, not recruiting
3
569
Europe, Canada, Japan, US, RoW
Spartalizumab, PDR001, Placebo, Dabrafenib, Trametinib
Novartis Pharmaceuticals
Melanoma
08/20
08/24
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
NCT06264778: Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

Not yet recruiting
3
10
NA
Dabrafenib, fenestration decompression
Shandong University
Ameloblastoma
11/25
12/25
NCT04940052: Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

Calendar Jan 2024 - Dec 2024: Data from trial in combination with Tafinlar for differentiated thyroid cancer
Active, not recruiting
3
153
Canada, US, RoW
Dabrafenib, Trametinib, Trametinib placebo, Dabrafenib placebo
Novartis Pharmaceuticals
Differentiated Thyroid Cancer
05/27
06/27
NCT06475989: Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Not yet recruiting
3
264
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Questionnaire Administration, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Refractory Differentiated Thyroid Gland Carcinoma
09/30
09/30
DREAMseq, NCT02224781: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Active, not recruiting
3
300
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
12/24
12/24

Download Options